34 results about "Sialic acid binding" patented technology

Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.

A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.

Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.

In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.

The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.

The invention discloses an aptamer of sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) protein. The aptamer comprises nucleotide sequences as shown in SEQ IDNO: 1- SEQ ID NO: 7. The aptamer provided by the invention can provide rapid and accurate detection on Siglec-15 protein. Meanwhile, The aptamer can block the interaction with T cell surface receptors, and reactivate proliferation of T cells to a certain extent, thereby normalizing immunity in tumor microenvironment without causing serious autoimmune response. The aptamer for Siglec-15 can be used as a medicine for cancers with high Siglec-15 expression in tumor microenvironment, and becomes a potential nucleic acid medicine for tumor immunotherapy. The aptamer of the present invention is possibly effective for patients who have no response to anti-PD-L1 treatment, and further supplements existing tumor diagnosis and immunotherapy systems.

The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.

The invention provides a recombinant protein and porcine epidemic diarrhea vaccine composition. The recombinant protein is a fusion protein that is tandemly formed by a truncated fragment from porcine epidemic diarrhea virus S protein (Spike, spike protein) and an Fc fragment of pig IgG. The truncated fragment of S protein is preferably selected from the S1 subunit of S protein. The N-terminal domain (NTD) with sialic acid binding activity in the base, the neutralizing epitope domain (COE) and multiple B cell recognition epitopes in the S2 subunit. The vaccine composition includes recombinant protein and adjuvant. After the recombinant protein of the present invention immunizes mice, it can produce higher levels of IgG antibodies and neutralizing antibody titers, CD 3+ cd 4+ 、CD 3+ cd 8+ The proportion of lymphocytes and the concentration of IFN-γ and IL-4 in lymphocytes showed a significant increase.

An isolated composition-of-matter comprising a sialic acid bound to a sialic acid binding domain of a polypeptide is provided. Uses thereof and kits comprising same are also provided.

Methods and kits for diagnosing and treating type I diabetes based upon the expression of macrophage-specific Chymotrypsin-Like Elastase Family, Member 3B, either alone or in combination with sialic acid-binding immunoglobulin-like lectin-1, are provided.

The present disclosure a cohort of sialic acid binding molecules which comprise one or more modified carbohydrate binding modules (CBMs). The modified CBMs reduce the risk of adverse events related to the host immune response and / or the production of anti-drug antibodies (ADAs). The modified CBMs can be used in therapy or as medicaments and find specific application as molecules for the modulation of an immune response and / or cell growth. The modified CBMs may also be used as adjuvants, for example mucosal adjuvants and in the treatment and / or prevention of cancer, sepsis and / or diseases caused or contributed to by a pathogen that binds cell surface sialic acid-containing receptors.

In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.